Jackson Hammond is a Senior Policy Analyst at Paragon Health Institute. He has been active in the federal and state health policy space since 2017.
Prior to joining Paragon, Jackson was a health care policy analyst for American Action Forum (AAF). While at AAF, his work focused on payer issues including private insurance, Medicare, and Medicare Advantage. Furthermore, Jackson wrote extensively about the 340B Program and contributed to AAF’s research on a variety of drug pricing issues.
On August 16, 2024, Paragon’s Prognosis “Bailing Out Bad Policy,” by Jackson Hammond, was quoted in the New York Post.
From the article:
“In a move critics say is designed to shield the Biden-Harris administration from election fallout, the administration has leveraged taxpayer funds to mask upcoming increases in Medicare premiums,” reports Jamie Joseph at Fox News. The Inflation Reduction Act was “intended to cap out-of-pocket drug costs,” but it’ll let insurers “significantly hike monthly premiums, with average bids for Part D plans expected to triple by 2025.” To avoid “voter backlash,” the Center for Medicare and Medicaid Services rolled out a three-year “demonstration project” to subsidize those premiums. Yet critics note that’ll simply shift the cost to taxpayers — up to $10 billion, one estimates. As a Paragon Health Institution analysis warns, CMS’s costly, “fake” voluntary “demonstration” is “neither a demonstration nor voluntary” — but rather a “massive subsidization scheme.”
Subscribe
Sign up now for your health policy updates.
